Question 1

What does the FDA-approved label cover for semaglutide?

Accepted Answer

Two approvals, two amounts, and telling them apart is the first job on this page. A 2021 trial in the Lancet refers to semaglutide 1·0 mg (the dose approved for diabetes treatment). That is the weekly injected amount tied to type 2 diabetes; the weight-management approval came later. A 2022 review records that the STEP results led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. A 2023 review covers the safety of semaglutide 2.4 mg/week for obesity, and a JAMA review the same year lists it among six medications currently approved by the US Food and Drug Administration for long-term use. We report it for the same reason we report that a compound is not approved for anything: it is a statement about what a regulator decided, rather than a view of ours.

Question 2

What is actually on a semaglutide dosing chart?

Accepted Answer

Most charts online are a ladder of weekly amounts with dates beside them, laid out as though one sequence fitted everybody. The published record is narrower, and it comes in pieces that are easy to run together. The injected amounts in phase 3 reports are 0·5 mg, 1·0 mg, 2·4 mg and 7·2 mg once weekly. A 2022 review places the first two: the SUSTAIN and PIONEER clinical trials studied the use of 1.0 mg, once-weekly, subcutaneous and oral semaglutide (a new GLP-1 homolog), respectively, on participants with type 2 diabetes. The same review records that the STEP trial examined the effects of 2.4 mg, once-weekly, subcutaneous semaglutide on patients with obesity. A chart carrying those numbers reports an approval beside a set of trial assignments, two different kinds of statement, and a chart that continues past them reports neither.

Question 3

What was the starting amount in the trials?

Accepted Answer

Nobody in the published programme began where they finished, but these reports name the assigned target far more often than the steps leading up to it. The lowest injected arm anywhere in the phase 3 record is 0·5 mg. In the 2017 diabetes trial, participants were given once-weekly subcutaneously injected semaglutide (0·5 mg or 1·0 mg), or volume-matched placebo, for 30 weeks. The weight-management trials arrived at their target the same way: the 2021 obesity trial took 1961 adults and assigned them, in a 2:1 ratio, to 68 weeks of treatment with once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo. What these papers therefore supply is an assignment and a duration, rather than a week-by-week chart anybody could lift off the page. The sequence a prescriber follows belongs to a label, and a label is not what a trial report is.

Question 4

What is the maximum dose of semaglutide?

Accepted Answer

Higher than most charts show, and the ceiling differs by route. A 2025 phase 3b trial assigned people (5:1:1) to receive once-weekly subcutaneous semaglutide 7·2 mg, 2·4 mg, or placebo, with a lifestyle intervention, for 72 weeks. That 7·2 mg arm is the largest injected amount in the published record. By mouth the numbers run on another scale. A 2025 trial frames its own design that way, noting that oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. Read those figures as research amounts rather than as a ceiling anybody has cleared. What an investigation was willing to assign, under supervision and with material of known identity, is a different question from what a label covers.

Question 5

What amount was used for weight loss?

Accepted Answer

2·4 mg once weekly, in trial after trial, across four continents and ten years. The two-year trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity. A 2024 trial in a mostly east Asian group gave a subcutaneous injection of either semaglutide 2·4 mg or placebo once a week for 44 weeks. One trial put the weight amount against the diabetes amount directly, giving semaglutide 2·4 mg, or semaglutide 1·0 mg, or visually matching placebo, once a week for 68 weeks. That last design is the useful one, because it holds everything else still and varies only the amount. It is also the clearest demonstration that the two approved figures were tested as separate propositions rather than two rungs of one ladder.

Question 6

How often was semaglutide given, and by what route?

Accepted Answer

Once a week under the skin, or once a day by mouth, and nothing else shows up in the published record. A 2021 review notes that it is the only GLP-1RA currently available as both subcutaneous and oral formulation. GLP-1RA stands for glucagon-like peptide-1 receptor agonist, the family it belongs to. The oral route carries conditions the injection does not. A 2024 systematic review reports that food and various dosing conditions including water volume and dosing schedules can affect the oral semaglutide exposure, meaning how much of a tablet reaches the blood. Nothing among the research behind this page compares one injection site with another, splits a weekly amount across two days, or tries a different interval. Those are not questions the literature has answered badly; they are questions no study we could find has put to it, which amounts to an absence of investigation rather than an absence of effect.

Question 7

Where was semaglutide injected, and at what time of day?

Accepted Answer

The 2017 diabetes trial is the single report in this literature that describes the practice at all. Participants did their own injections and were encouraged to administer them on the same day of each week in the same area of their body; the time of day and proximity of meal times was not specified. Read that closely, because it settles two separate questions simultaneously and in opposite directions. Keeping to one area of the body was an instruction handed to participants, while the hour of the day was deliberately left open, which means the investigation was never constructed to establish whether either one matters. So the published record contains no comparison of one site against another, nor of morning against evening. Those are different questions from the one that trial asked, and neither has since been put to an investigation of its own.

Question 8

What is the schedule for semaglutide tablets?

Accepted Answer

Once a day, at two amounts in the published record. The heart outcomes trial is comparing oral semaglutide (14 mg once daily) with placebo, both in addition to standard of care, and 9650 participants were enrolled. The 2025 obesity trial gave oral semaglutide (25 mg) or placebo once daily, plus lifestyle interventions, in a 2:1 split. A registered phase 1 study sets out to compare how much semaglutide is found in the blood with different tablets of oral semaglutide in healthy participants. That is the question a tablet raises and a weekly injection does not. Those milligram figures do not line up against the injected ones. 25 mg daily by mouth and 2·4 mg weekly by injection describe two separate routes, measured separately, and setting them in one column manufactures a comparison no study among the research behind this page has published.

Question 9

Does the amount depend on body weight?

Accepted Answer

Not in any published schedule, and the review that looked hardest at the question stops short of saying so. A 2024 systematic review reports that body weight may affect semaglutide exposure, but further studies are needed to confirm this. The same review is far more definite in the other direction. It records limited drug-drug interactions and no dosing adjustments in patients with upper gastrointestinal disease, renal impairment or hepatic impairment, which covers the gut, the kidneys and the liver in one line. So there is no milligram-per-kilogram figure to report, and we would not publish one anyway. A per-kilogram conversion is how an animal amount gets dressed up as a human one, and here the human figures are already on the record rather than inferred from a mouse.

Question 10

What does microdosing semaglutide mean?

Accepted Answer

It means using amounts below the ones that were studied, and no trial among the research behind this page has tested one. The smallest injected arm in the phase 3 record is 0·5 mg once weekly, from the 2017 trial that gave semaglutide (0·5 mg or 1·0 mg), or volume-matched placebo, for 30 weeks. Below that figure the published literature is empty. Routine care is a separate matter: a 2025 review of practice outside trials records the use of much lower doses than those evaluated in clinical trials, alongside high discontinuation rates of GLP-1RAs (20%-50%) within the first year. Read those two findings together rather than apart, because that review is describing what people did in ordinary practice, not an amount anybody assigned, measured and followed up. A microdosing chart borrows the authority of the second while only ever describing the first.

Question 11

Is there a dosing chart for compounded semaglutide?

Accepted Answer

No, and the reason is the whole point of this page. The approved schedule belongs to the approved product, and a compounded or research-grade vial has no approved label, so nothing in that schedule has been established as applying to what is inside it. The enforcement record shows why that is practical rather than legalistic. Compounded semaglutide turns up in FDA listings as Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, as Semaglutide, 5 mg/mL, pre-filled syringe, as Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, and as Semaglutide/Cyanocobalamin 24/2 MG/ML Injectable, 0.4 ML syringe. Those are four concentrations across four listings. An amount in milligrams therefore tells you nothing about the volume it comes in until you work out which concentration you are holding, and no source among the research behind this page ties a concentration to a seller.

Question 12

What is the starting dose of compounded semaglutide?

Accepted Answer

There is no published answer, and the honest version of that is worth more than a number. No regulator has approved a compounded semaglutide vial, so no approved label states a starting amount for one. No trial among the research behind this page has given compounded semaglutide to anybody and reported what happened next. One enforcement record makes the difficulty concrete. In July 2025 a pharmacy recalled Semaglutide, 2.5 mg/mL injection, 0.8 mL, and the reason filed against it was Subpotent Drug, meaning the vial held less than its label said. So the milligrams printed on an unlabelled vial are a claim by whoever filled it, rather than a measurement anybody checked. An amount you cannot verify is not an amount you can follow.

Question 13

How long did people stay on these amounts?

Accepted Answer

Between 30 weeks and two years: the 2017 diabetes trial ran 30 weeks, the 2021 obesity trial ran 68 weeks, a 2024 trial in a predominantly east Asian population ran 44 weeks, and the 2025 higher-dose trial ran 72 weeks. The longest published exposure is two years. In that trial the mean change in body weight from baseline to week 104 was -15.2% in the semaglutide group (n = 152) versus -2.6% with placebo (n = 152), and 92.8% of whom completed the trial attended the end-of-trial safety visit. Nothing among the research behind this page follows anybody past 104 weeks of continuous weekly injection. No trial among the research behind this page has examined a break, a taper or a cycle either, so there is no interval to report rather than a short one. Two years is simply where the record stops, and a record stopping is not the same as nothing happening afterwards.

Question 14

Why do the published amounts vary?

Accepted Answer

Because the trials were asking different questions of the same compound. The diabetes programme was built around blood sugar, and a 2021 head-to-head trial randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. The obesity programme settled on 2·4 mg and then looked either side of it. A 2025 comparison gave the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks, while a combination trial paired semaglutide at a dose of 2.4 mg and cagrilintide at a dose of 2.4 mg in one weekly injection. So the range widens or narrows with the research question, rather than with anything about a particular person, and a number is worth no more than the question it answered.

Semaglutide protocols in the published literature